FAP imaging in rare cancer entities—first clinical experience in a broad spectrum of malignancies

[1]  Jun Zhao,et al.  Comparison of [ , 2021 .

[2]  M. Gleave,et al.  High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  J. Debus,et al.  Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  D. Jäger,et al.  68Ga-FAPI-PET/CT in patients with various gynecological malignancies , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  D. Jäger,et al.  [153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  Y. Guan,et al.  The superiority of [68Ga]Ga-FAPI-04 over [18F]-FDG in a case of neuroendocrine tumour with hepatic metastasis , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  H. G. van der Poel,et al.  Staging 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Changes Treatment Recommendation in Invasive Bladder Cancer. , 2021, European urology oncology.

[8]  D. Sia,et al.  Cell of origin in biliary tract cancers and clinical implications , 2021, JHEP reports : innovation in hepatology.

[9]  Hua Wu,et al.  Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  Haitao Zhao,et al.  A methodological investigation of healthy tissue, hepatocellular carcinoma, and other lesions with dynamic 68Ga-FAPI-04 PET/CT imaging , 2020, EJNMMI Physics.

[11]  C. Gündoğan,et al.  68Ga-FAPI PET/CT Versus 68Ga-DOTATATE PET/CT in the Evaluation of a Patient With Neuroendocrine Tumor. , 2020, Clinical nuclear medicine.

[12]  Alisa S. Bettermann,et al.  Uncovering the invisible—prevalence, characteristics, and radiomics feature–based detection of visually undetectable intraprostatic tumor lesions in 68GaPSMA-11 PET images of patients with primary prostate cancer , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  Ping Guo,et al.  Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  M. Röhrich,et al.  FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients , 2020, The Journal of Nuclear Medicine.

[15]  S. A. Koerber,et al.  Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  J. Witjes,et al.  European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. , 2020, European urology.

[17]  U. Haberkorn,et al.  Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients , 2019, The Journal of Nuclear Medicine.

[18]  Yuli Lin,et al.  Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment , 2019, Neoplasia.

[19]  Thomas Lindner,et al.  Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention , 2019, The Journal of Nuclear Medicine.

[20]  Frederik L. Giesel,et al.  68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer , 2019, The Journal of Nuclear Medicine.

[21]  Danijela Matic Vignjevic,et al.  Cancer associated fibroblasts: is the force the path to the dark side? , 2019, Current opinion in cell biology.

[22]  F. Silvestris,et al.  The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications , 2019, Neuroendocrinology.

[23]  Thomas Lindner,et al.  Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein , 2018, The Journal of Nuclear Medicine.

[24]  Frederik L. Giesel,et al.  68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers , 2018, The Journal of Nuclear Medicine.

[25]  C. Thirlwell,et al.  Neuroendocrine tumors and fibrosis: An unsolved mystery? , 2017, Cancer.

[26]  P. Gascard,et al.  Carcinoma-associated fibroblasts: orchestrating the composition of malignancy , 2016, Genes & development.

[27]  D. Hughes,et al.  Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[28]  G. Gores,et al.  Desmoplastic stroma and cholangiocarcinoma: Clinical implications and therapeutic targeting , 2014, Hepatology.

[29]  A. Orimo,et al.  Carcinoma-Associated Fibroblasts Are a Promising Therapeutic Target , 2013, Cancers.

[30]  E. Long.  International Society for Pharmacoeconomics and Outcomes Research , 2012 .

[31]  B. Adeyemi,et al.  Head and neck cancer--a clinicopathological study in a tertiary care center. , 2008, Journal of the National Medical Association.

[32]  L. Old,et al.  Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. , 1990, Proceedings of the National Academy of Sciences of the United States of America.